Core Insights - Amicus Therapeutics, Inc. (NASDAQ:FOLD) is recognized as a high-potential biotech stock, with recent upgrades from analysts indicating strong market confidence [1][2]. Analyst Ratings - Needham analyst Gil Blum upgraded Amicus Therapeutics to a Buy rating with a price target of $14.00 on September 18 [1]. - Morgan Stanley analyst Maxwell Skor maintained a Buy rating with a price target of $12.00 on September 17 [2]. - The consensus rating for Amicus Therapeutics is a Strong Buy, with a median price target of $8.41, suggesting an upside potential of 78.25% from current levels [2]. Company Overview - Amicus Therapeutics focuses on discovering, developing, and delivering medicines for metabolic diseases [3]. - The company’s product portfolio includes the first and only approved oral precision medicine for Fabry disease, a clinical-stage treatment for Pompe disease, and a gene therapy portfolio for rare diseases [3].